Amyotrophic lateral sclerosis

A class of cancer drugs in development called PARP inhibitors could be useful for treating and preventing brain disorders, including amyotrophic lateral sclerosis (ALS), and some forms of frontotemporal degeneration (FTD), a new study from the University of Pennsylvania indicates. The protein TDP-43, when mistakenly outside the nucleus, forms clumps in brain cells that are… Read more

Using a new method to measure electrical activity in cells, Northwestern Medicine scientists have discovered that some neurons affected by amyotrophic lateral sclerosis (ALS) display hypo-excitability. “The excitability changes observed in these patient neurons most likely represent the early steps in the disease process. The fact that these changes are detectable in stem cell-derived neurons… Read more

A protein known as Splicing Factor, proline- and glutamine-rich (SFPQ), which normally resides inside the cell nucleus, exits the nucleus in diseased motor neurons, a new study from The Francis Crick Institute shows. The finding is the result of a collaborative group of clinical neurologists, molecular biologists and computer scientists working together to solve the… Read more

The world’s attention was focused on amyotrophic lateral sclerosis (ALS) recently with the death of Stephen Hawking. The famous physicist had a rare form of slowly progressing ALS that resulted in a gradual loss of motor function. Perhaps the experience of the disease is best conveyed by Hawking himself: “I have lived with the prospect… Read more

Increased metabolic use in patients with amyotrophic lateral sclerosis (ALS) has been linked to faster disease progression and reduced lifespan, University of Queensland researchers report. The finding, according to the UQ Centre for Clinical Research’s Dr. Frederik Steyn, reveals important information about how the body responds to ALS, and could hold clues to new approaches… Read more